# NRSN catalysts: NeuroSense Therapeutics Ltd. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/nrsn/catalysts

> NeuroSense Therapeutics Ltd. (NRSN) has no upcoming catalysts in this calendar. The latest recorded is the NeuroSense Therapeutics Ltd. topline data readout, Q1 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, half-year only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for NRSN?

NeuroSense Therapeutics Ltd. (NRSN) has no upcoming catalysts in this calendar. The latest recorded is the NeuroSense Therapeutics Ltd. topline data readout, Q1 2026. SEC Form 8-K: "For example, this Report on Form 6-K states that the topline results for the RoAD study is expected in the first quarter of 2026." [Calendar and source filings](https://sec-api.dev/companies/nrsn/catalysts)

Source: SEC Form 8-K, accession 0001213900-25-118962, https://www.sec.gov/Archives/edgar/data/1875091/000121390025118962/ea0268801-6k_neuro.htm (retrieved 2026-11-12). Last confirmed 2025-12-08. Cite: https://sec-api.dev/companies/nrsn/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | NeuroSense Therapeutics Ltd. |
| Ticker | NRSN (Nasdaq) |
| SEC CIK | 1875091 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/nrsn |

## Cash runway

Cash $166K as of 2025-12-31; quarterly burn $1.9M; about 0.3 months of runway at that rate (XBRL company facts, accession 0001213900-26-036970).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Dec 2023 | [NST003 topline data readout](https://sec-api.dev/pdufa/nst003) | NRSN | ALS, reporting | completed, met | "In December 2023, we announced topline clinical efficacy results in our Phase 2b PARADIGM (NST003) trial of PrimeC for the treatment of ALS, reporting that we met the primary safety and tolerability endpoints and achieved secondary clinical efficacy endpoints." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1875091/000121390025029464/ea0237295-20f_neuro.htm)) |
| 2H 2025 | [Ciprofloxacin trial start](https://sec-api.dev/pdufa/ciprofloxacin) | NRSN |  | scheduled | "Phase 3 trial commencement - Following positive regulatory feedback from the FDA, NeuroSense plans to begin a multinational Phase 3 study of PrimeC in ALS in the second half of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1875091/000121390025070315/ea025084301ex99-1_neurosense.htm)) |
| September 30, 2025 | [Primec primary completion](https://sec-api.dev/pdufa/primec) | NRSN | Alzheimer Disease | withdrawn | "NCT06185543 (A Phase 2, Randomized, Prospective Double-Blind, Single-Center, Placebo-controlled Study to Evaluate Safety, Tolerability, Target Engagement, and Efficacy of PrimeC in Patients With Mild to Moderate Alzheimer's Disease.): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-09-30 (ACTUAL); Lead Sponsor NeuroSense Therapeutics Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06185543)) |
| Q1 2026 | [NeuroSense Therapeutics Ltd. topline data readout](https://sec-api.dev/companies/nrsn/catalysts) | NRSN |  | scheduled | "For example, this Report on Form 6-K states that the topline results for the RoAD study is expected in the first quarter of 2026." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1875091/000121390025118962/ea0268801-6k_neuro.htm)) |

## Drugs

- [Ciprofloxacin](https://sec-api.dev/pdufa/ciprofloxacin): 
- [NST003](https://sec-api.dev/pdufa/nst003): als, reporting
- [Primec](https://sec-api.dev/pdufa/primec): Alzheimer Disease

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/nrsn/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "NRSN catalysts: NeuroSense Therapeutics Ltd. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/nrsn/catalysts

```bibtex
@misc{secapidev_companies_nrsn_catalysts_20261116,
  title        = {NRSN catalysts: NeuroSense Therapeutics Ltd. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/nrsn/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_nrsn_catalysts_20261116","title":"NRSN catalysts: NeuroSense Therapeutics Ltd. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/nrsn/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
